Pediatric melanoma-The whole (conflicts of interest) story.
作者信息
Rose Klaus, Grant-Kels Jane M
机构信息
klausrose Consulting, Riehen, Switzerland.
University of Connecticut Health Center, Farmington, Connecticut.
出版信息
Int J Womens Dermatol. 2018 Nov 19;5(2):110-115. doi: 10.1016/j.ijwd.2018.10.020. eCollection 2019 Jun.
Abstract
摘要
相似文献
1
Pediatric melanoma-The whole (conflicts of interest) story.儿童黑色素瘤——完整的（利益冲突）故事。
Int J Womens Dermatol. 2018 Nov 19;5(2):110-115. doi: 10.1016/j.ijwd.2018.10.020. eCollection 2019 Jun.
2
Pediatric Melanoma and Drug Development.小儿黑色素瘤与药物研发
Children (Basel). 2018 Mar 20;5(3):43. doi: 10.3390/children5030043.
3
Do the European Medicines Agency Decisions Hurt Pediatric Melanoma Patients?欧洲药品管理局的决定是否伤害了儿童黑色素瘤患者？
Clin Ther. 2017 Feb;39(2):253-265. doi: 10.1016/j.clinthera.2017.01.009. Epub 2017 Jan 31.
4
The Meanings of "Pediatric Drug Development".“儿科药物研发”的含义
Ther Innov Regul Sci. 2019 Nov;53(6):767-774. doi: 10.1177/2168479018812060. Epub 2018 Dec 9.
5
The impact of the written request process on drug development in childhood cancer.书面申请流程对儿童癌症药物研发的影响。
Pediatr Blood Cancer. 2013 Apr;60(4):531-7. doi: 10.1002/pbc.24346. Epub 2013 Jan 17.
6
European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.欧盟儿科立法危及全球范围内儿童癌症护理的未来及时进展。
Clin Ther. 2014 Feb 1;36(2):163-77. doi: 10.1016/j.clinthera.2014.01.009.
7
EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations.EMA 和 FDA 精神药物试验指南：指南制定和试验设计建议评估。
Epidemiol Psychiatr Sci. 2021 Apr 30;30:e35. doi: 10.1017/S2045796021000147.
8
Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.黑色素瘤疫苗——AVAX科技公司：DNP-VACC、M-Vax。
BioDrugs. 2003;17(1):69-72. doi: 10.2165/00063030-200317010-00007.
9
Are Regulatory Age Limits in Pediatric Melanoma Justified?小儿黑色素瘤的监管年龄限制合理吗？
Curr Ther Res Clin Exp. 2019 Jan 18;90:113-118. doi: 10.1016/j.curtheres.2019.01.003. eCollection 2019.
10
Global Pediatric Drug Development.全球儿科药物研发
Curr Ther Res Clin Exp. 2019 Feb 13;90:135-142. doi: 10.1016/j.curtheres.2019.02.001. eCollection 2019.
引用本文的文献
1
Did pediatric drug development advance epilepsy treatment in young patients? It is time for new research goals.儿科药物研发是否推动了年轻患者癫痫治疗的进展？是时候设定新的研究目标了。
World J Methodol. 2024 Jun 20;14(2):92371. doi: 10.5662/wjm.v14.i2.92371.
2
Identification of Potential Core Genes Between Primary and Metastatic Malignant Melanoma and Analysis of Their Immune Correlation.原发性和转移性恶性黑色素瘤潜在核心基因的鉴定及其免疫相关性分析
Int J Gen Med. 2022 Jan 11;15:379-391. doi: 10.2147/IJGM.S338890. eCollection 2022.
3
COVID-19 and Treatment and Immunization of Children-The Time to Redefine Pediatric Age Groups is Here.新型冠状病毒肺炎与儿童治疗及免疫——重新定义儿童年龄组的时候到了。
Rambam Maimonides Med J. 2021 Apr 29;12(2):e0010. doi: 10.5041/RMMJ.10433.
4
Too Many Avoidable Suicides Occur Worldwide in Young Patients.全球范围内，年轻患者中发生了太多可避免的自杀事件。
Rambam Maimonides Med J. 2019 Oct 29;10(4):e0026. doi: 10.5041/RMMJ.10374.
5
The Challenges of Pediatric Drug Development.儿科药物研发的挑战。
Curr Ther Res Clin Exp. 2019 Jan 26;90:128-134. doi: 10.1016/j.curtheres.2019.01.007. eCollection 2019.
6
Questionable Industry-Sponsored Postneonatal Pediatric Studies in Slovenia.斯洛文尼亚存在问题的行业资助的新生儿期后儿科研究。
Curr Ther Res Clin Exp. 2019 Jan 18;90:86-91. doi: 10.1016/j.curtheres.2019.01.002. eCollection 2019.
7
Rational Use of Medicine in Children-The Conflict of Interests Story. A Review.儿童用药的合理使用——利益冲突故事。综述。
Rambam Maimonides Med J. 2019 Jul 18;10(3):e0018. doi: 10.5041/RMMJ.10371.
本文引用的文献
1
Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.I 期/II 期研究中每周纳武利尤单抗治疗儿童复发性/难治性实体瘤的 I 期结果：与癌症儿童创新疗法的合作。
Eur J Cancer. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21.
2
Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry.开发用于治疗儿童（≥3个月至<18岁）特应性皮炎的药物：行业指南草案。
Pediatr Dermatol. 2018 May;35(3):303-322. doi: 10.1111/pde.13452. Epub 2018 Mar 30.
3
Contrasting features of childhood and adolescent melanomas.儿童和青少年黑色素瘤的对比特征。
Pediatr Dermatol. 2018 May;35(3):354-360. doi: 10.1111/pde.13454. Epub 2018 Mar 23.
4
Pediatric Melanoma and Drug Development.小儿黑色素瘤与药物研发
Children (Basel). 2018 Mar 20;5(3):43. doi: 10.3390/children5030043.
5
Most adolescents' melanomas are conventional malignant adult-type melanomas.大多数青少年的黑色素瘤是典型的成人型恶性黑色素瘤。
Eur J Cancer. 2018 May;95:117-119. doi: 10.1016/j.ejca.2018.01.080. Epub 2018 Feb 20.
6
Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank.加强儿科心血管药物研发的建议：多利益相关方智库报告
J Am Heart Assoc. 2018 Feb 10;7(4):e007283. doi: 10.1161/JAHA.117.007283.
7
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.替沙格赛定用于治疗儿童和年轻成人B细胞淋巴细胞白血病
N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.
8
Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE.青少年-成人联合早期临床试验，以改善癌症青少年获得新药的机会：多利益相关方平台-ACCELERATE的提议
Ann Oncol. 2018 Mar 1;29(3):766-771. doi: 10.1093/annonc/mdy002.
9
Review: Oncolytic virotherapy, updates and future directions.综述：溶瘤病毒疗法、进展与未来方向。
Oncotarget. 2017 May 31;8(60):102617-102639. doi: 10.18632/oncotarget.18309. eCollection 2017 Nov 24.
10
Monitoring and management of hypertension with obesity in adolescents.青少年肥胖合并高血压的监测与管理
Integr Blood Press Control. 2017 Nov 20;10:33-39. doi: 10.2147/IBPC.S125094. eCollection 2017.
Zotero 插件